

**Maryland Board of Pharmacy  
Public Board Meeting**

**Meeting Minutes  
Date: 08/19/15**

Name	Title	Present	Absent	Present	Absent
<b>Board Committee</b>					
Ashby, D.	Commissioner	X			
Bouyoukas, E.	Commissioner	X			
Gavgani, M. Z.	Commissioner/President	X			
Jones, David H.	Commissioner/Secretary	X			
Peters, R.	Commissioner		X		
Robinson, T.	Commissioner	X			
Rochester, C.	Commissioner	X			
Roy, S.	Commissioner		X		
Smith, J.	Commissioner/Treasurer	X			
St. Cyr, II, Z. W.	Commissioner	X			
Yankellow, E.	Commissioner	X			
Zagnit, B.	Commissioner	X			
<b>Board Counsel</b>					
Bethman, L.	Board Counsel		X		
Felter, B.	Staff Attorney				
<b>Board Staff</b>					
Naesea, L.	Executive Director	X			
Wu, Y.	Compliance Manager	X			
	Licensing Manager				
Waddell, L	Administration and Public Support Manager	X			
Jeffers, A.	Legislation/Regulations Manager	X			
Johnson, J.	MIS Manager	X			



Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>processed. Daily processing of applications for other license types has resumed. The Board apologizes for the delay in processing and is working to processes all applications more timely.</p> <p>The FY 2017 budget appropriation request was submitted to the Department of health and Mental Hygiene. The request contained much of what was requested for FY 2016 in addition to two new administrative specialists and an increase in the amount allotted for personnel/Board training related to its reorganization and other known changes that will take place in FY 2017.</p> <p>There is also a place holder in the amount of \$1 million for the new MIS system which will probably will be bid on by the end of the 3<sup>rd</sup> or 4<sup>th</sup> quarter of FY 2017 ( begins July 1, 2016).</p> <p><b>2. Meetings Updates</b></p> <p>The Board Directors meeting was held August 10, 2015. Highlights impacting the Board of Pharmacy included: the addition of Wi-Fi accessible in the building meeting rooms; and an announcement that the building telephone system will be replace in calendar year 2017.</p> <p>A meeting with Department of Health and Mental Hygiene Secretary, Van Mitchell is scheduled August 24<sup>th</sup> to request the Department's continued support of the Board's reorganization plan and the planning for the acquisition of a new MIS system. The planned</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>system may serve as a model for other Maryland boards as well as Boards of Pharmacy in other states.</p> <p>The Board received a request from the Office of the Governor, to examine ways that fees can be reduced to better support small business in Maryland. A draft spreadsheet was discussed with the Executive Committee and will be presented during the Public meeting for consideration by the entire Board.</p> <p><b>3. Other Matters</b></p> <p>a. NABP has developed an Interconnect System for the Prescription Drug Monitoring Program. Maryland joined the system in August, which allows the CRISP System to be accessed by clinical users through an interface tab within the CRISP clinical query portal (named the Interstate PDMP). This system is helpful in tracking prescriptions that are taken by patients to neighboring states to be filled.</p> <p>b. L. Naesea will be retiring, effective December 31, 2015. She has served as Executive Director of the Maryland Board of Pharmacy for a little over 15 years.</p> <p>M. Gavvani expressed appreciation for the outstanding job done in the last 15 years given the limited resources and challenges presented, and also for her leadership.</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>M. Gavgani requested an update from D Jones, who is assigned to Chair the Search Committee responsible for recruitment of a replacement new Executive Director.</p> <p>D. Jones stated that the Committee has completed most of paperwork required to begin the recruitment process. Recruitment will be done through the state website and local and regional publications. There is a planned overlapping of the Executive Director position to provide a smooth transition and continuity with current Board activities. The position description and job duties have been revised and approved by the committee. Approval to begin recruitment and interviewing will follow from DHMH.</p> <p>D. Jones also mentioned that interviews for the newly approved Deputy Director of Operations will be held in the week following the Board meeting.</p>		
<p><b>B. Administration and Public Support (APS)</b></p>	<p><b>B. L. Waddell, APS Manager</b></p>	<p><b>1. Personnel Updates</b></p> <p>a. L. Waddell has been reclassified from Licensing to APS manager.</p> <p>The administrative specialist position formerly held by L. Waddell can now be reclassified to the Licensing manager position for recruitment.</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<ul style="list-style-type: none"> <li>b. Interviews for the Deputy Director of Operations will begin on August 20.</li> <li>c. Applications and resumes for the 4 temporary positions that were approved will be reviewed by unit managers for selections.</li> <li>d. Health Occupations Investigator interviews are being scheduled.</li> <li>e. The Lab Scientist Surveyor has been approved in the budget, pending approval of a Position Identification Number by the Department of Budget Management.</li> <li>f. C. Jackson has been selected for the vacant Administrative Specialist in the Licensing unit.</li> <li>g. The reorganization plan is still pending approval of the Department of Budget Management.</li> </ul> <p><b>2. Contracts and Procurement</b></p> <ul style="list-style-type: none"> <li>a. A summary of the fourth quarter expenditures (attached) and proposed FY 2016 budget was provided.</li> <li>b. Post care renewal notices for all licensees will be sent out via vendor beginning in September.</li> </ul>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<ul style="list-style-type: none"> <li>c. A vendor has been selected to receive registration payments for the annual Continuing Education Breakfast.</li> <li>d. A lockbox process being is being reviewed which require licensees to submit applications directly to the Board's Bank for more expedient processing of fees received. This should also positively impact the time frame for the entire application process.</li> <li>e. Credit card machines have been ordered to give the Board the capability to accept credit card payments received from walk-in applicants at the Board office.</li> </ul>		
<b>C. MIS</b>	<b>J. Johnson, MIS Manager</b>	<p><b>1. MIS Update</b></p> <ul style="list-style-type: none"> <li>a. The DHMH Department of Information Technology has approved the Request for Resumes (RFR) submitted for the programmer position. After awarded, the position will be used to update the mobile inspection program utilized by the inspectors.</li> <li>b. Software will be used to accept payments for the Board's Continuing Education breakfast. This service is contracted by DHMH and available to its units at no charge. Enrollment procedures must be completed before use.</li> </ul>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
---------	-------------------	------------	-------------------------------	---------

		<p>c. A new email address was created specifically to receive all notifications from CJIS. Until recently, some reports had been automatically sent to the Board's spam. The new process has resolved this.</p> <p>d. Refresher training for staff on use of the MIS database software was held in July.</p>																						
<p><b>D. Licensing</b></p>	<p><b>Y. Wu, Acting Licensing Unit Manager</b></p>	<p><b>1. Unit Updates</b></p> <p>The Licensing unit staff has been working diligently to have processed applications received by July 20 and staff members will be working over the weekend to hopefully get caught up to applications received by August 10.</p> <p><b>2. Monthly Statistics</b></p> <p><i>June 2015</i></p> <table border="1" data-bbox="611 1078 1184 1409"> <thead> <tr> <th>License Type</th> <th>New</th> <th>Renewed</th> <th>Reinstated</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>Pharmacist</td> <td>103</td> <td>466</td> <td>0</td> <td>10671</td> </tr> <tr> <td>Vaccination</td> <td>42</td> <td>39</td> <td>0</td> <td>3847</td> </tr> <tr> <td>Pharmacy</td> <td>18</td> <td>0</td> <td>0</td> <td>2022</td> </tr> </tbody> </table>	License Type	New	Renewed	Reinstated	Total	Pharmacist	103	466	0	10671	Vaccination	42	39	0	3847	Pharmacy	18	0	0	2022		
License Type	New	Renewed	Reinstated	Total																				
Pharmacist	103	466	0	10671																				
Vaccination	42	39	0	3847																				
Pharmacy	18	0	0	2022																				

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
---------	-------------------	------------	-------------------------------	---------

		<table border="1"> <tbody> <tr> <td data-bbox="562 215 722 305">Distributors</td> <td data-bbox="722 215 840 305">11</td> <td data-bbox="840 215 953 305">73</td> <td data-bbox="953 215 1068 305">0</td> <td data-bbox="1068 215 1230 305">1133</td> </tr> <tr> <td data-bbox="562 305 722 467">Pharmacy Technicians</td> <td data-bbox="722 305 840 467">172</td> <td data-bbox="840 305 953 467">298</td> <td data-bbox="953 305 1068 467">9</td> <td data-bbox="1068 305 1230 467">9231</td> </tr> <tr> <td data-bbox="562 467 722 636">Student Technicians</td> <td data-bbox="722 467 840 636">39</td> <td data-bbox="840 467 953 636">0</td> <td data-bbox="953 467 1068 636">1</td> <td data-bbox="1068 467 1230 636">982</td> </tr> </tbody> </table>	Distributors	11	73	0	1133	Pharmacy Technicians	172	298	9	9231	Student Technicians	39	0	1	982		
Distributors	11	73	0	1133															
Pharmacy Technicians	172	298	9	9231															
Student Technicians	39	0	1	982															

E. Compliance	Y. Wu, Compliance Manager	<p><b>1. Monthly Statistics</b></p> <p><b>Complaints &amp; Investigations:</b></p> <p>New Complaints - 32  Resolved (Including Carryover) – 24  Final disciplinary actions taken – 6  Reversals – 0  Summary Actions Taken – 2</p> <p><b>Inspections:</b></p> <p>Total - 176  Annual Inspections - 163  Opening Inspections - 6  Closing Inspections - 1  Relocation Inspections - 4  Board Special Investigation Inspections – 2  Division of Drug Control Closing Inspections – 5</p>		
---------------	------------------------------	---	--	--

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p><b>2. PEAC Update</b></p> <p><b>Total Pharmacist Rehabilitation Clients – 17</b>  Pharmacist – 17  Technician – 0  Pharmacy Student – 0  Clients Monitored by Board Req. PEAC Assistance – 2</p> <p><b>Drug Test Results - 13</b>  Number of Positive Results- 0</p> <p><b>Discharged Clients/Closed Cases- 2</b></p>		
<p><b>F. Legislation &amp; Regulations</b></p>	<p><b>A. Jeffers, Legislation &amp; Regulations Manager</b></p>	<p><b><u>REGULATIONS:</u></b></p> <p><b><u>10.34.19 Sterile Pharmaceutical Compounding proposed-form 10.34.19 061715</u></b></p> <p>Informal comments:</p> <p><b><u>Johns Hopkins Comment on Sterile Compounding Draft Proposed COMAR 10.34.19</u></b></p> <p><b><u>Don Taylor - Informal comment COMAR 10.31.19 061815</u></b></p> <p><b><u>Lee BOP Letter 10-34-19 Informal Comment</u></b></p> <p><b><u>MedChi - Informal Comment on Sterile Cpdg Draft Regs 7 8 2015</u></b></p> <p><b><u>Md Society of Oncology COMAR 10.34.19 072715</u></b></p>	<p>10.34.19  Motion to approve amended response by D Ashby, 2<sup>nd</sup> by J. Smith.</p>	<p>10.34.19  The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p><u>Board informal response:</u></p> <p><b><u>Draft Bd Resp - Informal Comments 10.34.19 081915</u></b></p> <p>Added a reference to USP 800 regarding hazardous drugs.</p> <p>Thank you for providing informal comments regarding draft revisions to COMAR 10.34.19 Sterile Pharmaceutical Compounding, revised to comply with statutory requirements as amended by SB 69/HB 181 State Board of Pharmacy – Sterile Compounding – Compliance by Nonresident Pharmacies and Repeal of Permit Requirement, 2015, Chapter 0005.</p> <p>This letter will address all the informal comments received from stakeholders in one letter including a description of revisions as a result of those comments. The letter is organized by regulation number.</p> <p><b><u>10.34.19.02 Incorporation by Reference</u></b></p> <p>A comment noted that the proposed regulations reference USP 797. The commenter asked if the intent of the proposal had any bearing on the storage, preparation, administration or disposal of hazardous drugs such as chemotherapy.</p> <p>Since 2007, as revised in 2009, COMAR 10.34.19 has incorporated by reference U.S. Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding—Sterile Preparations (USP 797 Standards), which has been incorporated by reference in 21 U.S.C. §351(b) (as amended); U.S. Pharmacopeia (USP) General Chapter 795 Pharmaceutical Compounding—Non-</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>Sterile Preparations (USP 795 Standards), which has been incorporated by reference in 21 U.S.C. §351(b) (as amended); U.S. Pharmacopeia (USP) Chapter 821 Radioactivity, which has been incorporated by reference in 21 U.S.C. §351(b) (as amended); and U.S. Pharmacopeia (USP) Chapter 823 Radiopharmaceuticals for Positron Emission Tomography—Compounding, which has been incorporated by reference in 21 U.S.C. §351(b) (as amended). This is not a new requirement for Maryland or federal law.</p> <p>If the intent of COMAR 10.34.19 has any bearing on the storage, preparation, administration or disposal of hazardous drugs such as chemotherapy, it would only be of a pharmacist performing sterile pharmaceutical compounding in a pharmacy. The handling of hazardous materials for other health professionals is regulated by their respective licensing Board and the Maryland Occupational Safety and Health (MOSH) under the Division of Labor and Industry of the Department of Labor, Licensing, and Regulation. Additionally, U.S. Pharmacopeia (USP) General Chapter &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings, will be forthcoming to address storage, preparation, administration or disposal of hazardous drugs such as chemotherapy.</p> <p><b><u>10.34.19.03 Definitions.</u></b>  There have been several comments regarding the nature of the definition of “compounding” included in the proposed regulations:</p> <p>(9) “Compounding” means the preparation, mixing, assembling, packaging, or labeling of a drug only:</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>(a) As the result of a practitioner’s prescription drug order or initiative based on the practitioner/patient relationship in the course of professional practice; or</p> <p>(b) For the purpose of, or incidental to, research, teaching, or chemical analysis and not for the sale or dispensing of the drug or device; or</p> <p>(c) In anticipation of a prescription drug order based on routine, regularly observed prescribing patterns.</p> <p>It was requested to add to the definition of “compounding” that “compounding does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product’s manufacturer and other manufacturer directions consistent with that labeling.”</p> <p>As stated above, USP 797 is incorporated by reference in COMAR 10.34.19. The Board may not add the exclusion above to its definition because USP 797 includes reconstitution as sterile compounding. Please note however, that 10.34.19 only governs pharmacists performing sterile compounding.</p> <p>It was also mentioned and questioned why the Board added the word “only” in the first part of the definition of “compounding.” Although the Board recognizes that the word “only” is superfluous, the Board is amiable to its deletion.</p> <p>It was noted that the draft regulation uses the term “sterile compounding,” but the legislation uses the term “compounded sterile preparations” for the same</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>definition. The existing regulations, COMAR 10.34.19.03B(6), already include a definition for “compounded sterile preparations.” The Board chose to use the term “sterile compounding” to be consistent with USP 797.</p> <p>Finally, a comment asked that the Board use the definition of “compounding” from Maryland 2014 Law SB 1108. Maryland 2015 Law, SB 69/HB 181 State Board of Pharmacy – Sterile Compounding – Compliance by Nonresident Pharmacies and Repeal of Permit Requirement, Chapter 0005, repealed Maryland 2014 Law SB 1108 and all the definitions therein.</p> <p><b><u>10.34.19.17C – Minimum Requirements for Inspections.</u></b>  Concern was expressed regarding the wording of Section C which reads:</p> <p style="padding-left: 40px;">“Within 90 days before the date of application, inspections of non-resident pharmacies may be conducted by:”</p> <p>This wording was used to be consistent with statutory language. The intent of the regulations is that the inspection be performed within 90 days of the date of the application which generally coincides with the date of the submission of the application.</p> <p><b><u>10.34.19.17D</u></b>  This section reads “The Board shall inspect non-resident pharmacies upon initial application and upon renewal.” The comment received noted that this may be construed to mean only the Board would perform the inspections. The Board, therefore, will revise this</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>section by adding in the words “or designee” after the word “Board.”</p> <p>“The Board or designee shall inspect non-resident pharmacies upon initial application and upon renewal.”</p> <p><b><u>10.34.19.18 – Reporting Requirements Pharmacies.</u></b>  A comment asked the Board to consider extending the deadline for reporting adverse events from five days to 14 days to allow a reasonable time period to develop and submit an action plan. In the interest of public safety, the Board will not extend the reporting deadline beyond 5 days. When there is evidence of environmental contamination it needs to be reported as soon as possible to keep the public safe. Action plans may be submitted as soon as possible, but may be submitted after the initial 5 days.</p> <p><b><u>10.34.19.18B</u></b>  Section B requires a pharmacy to report to the Board within 5 calendar days, yet does not delineate when the clock begins to toll. It was noted that it often takes several days to get reports back after testing by a third party vendor. In response to this comment, the Board will revise Section B to read:</p> <p>“B. Report to the Board within 5 calendar days:</p> <p>(1) Adverse events that have been discovered including corrective actions taken or proposed;”</p> <p>Please be advised that COMAR 10.34.19 governs <u>pharmacists and pharmacy sterile compounding</u> and the Board and this chapter have no jurisdiction over other health care professionals who</p>		



Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>Board approval requested to release for informal comment.</p> <p><b><u>DRAFT Proposal COMAR 10.34.33 Repository Regs 081915</u></b></p> <p>Zeno St. Cyr, II would like to see a newsletter article on moving the Drop-Off Sites to the Repository category.</p> <p><b><u>LEGISLATION: Update</u></b></p> <p><b><u>Practice Committee addressing through research and subcommittees:</u></b></p> <ol style="list-style-type: none"> <li>1) <b>Non-sterile compounding for office use; and</b></li> <li>2) <b>Two aspects of telepharmacy for legislation in 2017:</b> <ol style="list-style-type: none"> <li>A) <b>Central fill; and</b></li> <li>B) <b>Remote supervision</b></li> </ol> </li> </ol> <p><b><u>Midwife Nurse Formulary Committee 8-601</u></b></p> <p>The Nursing Board wants to delete the nurse midwife formulary committee because it hasn't met since 2008 and as of this point 99% of the nurses practicing midwifery are working in hospitals or birthing centers. Anna Jeffers informed Shirley Devaris at the Nursing Board that the Board is not comfortable with this language coming out.</p> <p>She agreed to leave as is.</p> <p><b><u>OTHER MATTERS:</u></b></p>	<p>Mitra Gavgani asked Ms. Jeffers to obtain the actual midwife nurse formulary from the Board of Nursing.</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>1) Dan Ashby will serve on the DHMH PDMP Advisory Committee.</p> <p>2) Revisions to Health Occupations Article, 1-806, Section A2, Annotated Code of Maryland. Legislative Services is considering correcting this section in the annual corrective bill. A motion was made whether the Board was supportive of this revision:</p> <p>“(a) Each health occupations board shall adopt specific sanctioning guidelines, including:  (1) A range of sanctions that is based on historical data or a normative process for each type of violation; and  (2) A list of mitigating and aggravating circumstances that may be used to decide if <b>THE APPROPRIATE</b> [a] sanction falls within or outside the established range of sanctions.”  HOC 1-806  Section A2</p>	<p>HOC 1-806  Motion to approve by J. Smith, 2<sup>nd</sup> by M. Gavvani.</p>	<p>HOC 1-806  The board voted to approve this motion.</p>
<p><b>III. Committee Reports</b>  <b>A. Practice Committee</b></p>	<p><b>D. Jones, Chair</b></p>	<p><b><u>Inquiries:</u></b></p> <p><b>Pharmacist Working Conditions Survey Part II</b></p> <p>David Jones reported on the recent findings of the Survey Part II. The Survey will still be collecting data into September.</p>		<p>The survey will be extended an additional two weeks to allow for additional responses.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
B. Licensing Committee	J. Smith, Chair	<p><b>1. Review of Pharmacist Applications:</b></p> <p>a. <b><i>I. Simonyan Abazyian</i></b>: Applicant applied for pharmacist licensure in May of 2015 after passing the NAPLEX in April. She failed to apply for a score transfer due to issues. The applicant is currently asking that the Board negotiate with NABP to transfer her NAPLEX score because she cannot physically nor financially re-take the exam. <u>Licensing Committee's recommendation:</u> No recommendations pending the outcome of Ms. Naesea reaching out to NABP. <u>UPDATE:</u> NABP and will have her score transferred.</p> <p>b. <b><i>M. Benson</i></b> – Applicant sent in a request on June 29, 2015 seeking additional time to renew his license which expired on June 30, 2015. At the time, he has not sent in the fee and has not yet taken live CEs. On August 4, the applicant wrote an appeal letter to the Board's July decision to deny his request for the extension and that he needed to reinstate. <u>Licensing Committee's recommendation:</u> Deny the appeal request, he must reinstated.</p> <p>c. <b><i>A. Olin</i></b> - Licensee petitioning the Board for reconsideration of her application for reinstatement due to issues.</p>	<p>1a. Motion by committee to have score transferred, 2<sup>nd</sup> by D. Ashby.</p> <p>1b. Motion by committee to deny request, 2<sup>nd</sup> by D. Ashby.</p> <p>1c. Motion by committee to approve, 2<sup>nd</sup> by D. Ashby.</p>	<p>1a. The Board voted to approve this motion.</p> <p>1b. The Board voted to approve this motion.</p> <p>1c. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p><u>Licensing Committee's recommendation:</u> Approve licensee for reinstatement and "reactivate" her application.</p> <p>d. <b>A. Smolen</b> - Licensee is requesting that his reinstatement application be processed without the additional reinstatement fees due to issues. On July 2, 2015, the reinstatement application was submitted with the entire \$527 fee.</p> <p><u>Licensing Committee's recommendation:</u> Contact licensee for documentation substantiating request. <u>UPDATE:</u> contacted licensee and does not want to provide.</p> <p><b>2. Review of Pharmacy Technician Applications:</b></p> <p>a. <b>N. Salih</b> - Applicant would like to apply using a Bachelor's in Pharmacy degree in Egypt rather than a tech training/certification program.</p> <p><u>Licensing Committee's recommendation:</u> Deny the request to use Pharmacy degree in lieu of him taking PTCB or Board approved technician training program.</p> <p><b>3. Review of Distributor Applications:</b> <i>None.</i></p> <p><b>4. Review of Pharmacy Applications:</b></p> <p>a. <b>Zonetak Pharmacy on Pratt Street</b> - Applicant submitted a change of ownership application where it</p>	<p>1d. Motion by committee to deny request, 2<sup>nd</sup> by D. Jones.</p> <p>2a. Motion by committee to deny request, 2<sup>nd</sup> by D. Ashby.</p> <p>4a. Motion by committee to deny, 2<sup>nd</sup> by D. Ashby.</p>	<p>1d. The Board voted to approve this motion.</p> <p>2a. The Board voted to approve this motion.</p> <p>4a. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>indicated that the new owner, Dr. E. Dixon, an ophthalmologist, owns 100% of the company.  <u>Licensing Committee's recommendation:</u> Not to approve, the owner is a physician.</p> <p><b>b. <u>Zonetak Pharmacy on Garrison Boulevard</u></b> - Applicant submitted a change of ownership application where it indicated that the new owner, Dr. E. Dixon, an ophthalmologist, owns 100% of the company.  <u>Licensing Committee's recommendation:</u> Not to approve, owner is a physician.</p> <p><b>c. <u>Maryland Vital Care Pharmacy</u></b> - Applicant submitted a change of ownership application where it indicated that the new owner, Dr. E. Dixon, an ophthalmologist, owns 100% of the company.  <u>Licensing Committee's recommendation:</u> Not to approve, owner is a physician</p> <p><b>5. Review of Pharmacy Technicians Training Programs:</b> <i>None.</i></p> <p><b>6. New Business:</b></p> <p>a. <b><u>Pharmacy Technician Program Survey Questions</u></b> - <u>Licensing Committee's recommendation:</u> For Board review and approval</p>	<p>4b. Motion by committee to deny, 2<sup>nd</sup> by D. Ashby.</p> <p>4c. Motion by committee to deny, 2<sup>nd</sup> by D. Ashby.</p> <p>6a. Motion by committee to approve, 2<sup>nd</sup> by D. Jones.</p>	<p>4b. The Board voted to approve this motion.</p> <p>4c. The Board voted to approve this motion.</p> <p>6a. The Board voted to approve this motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>b. <i>NABP Innovation in Test Development.</i> FYI only</p>		
<p><b>C. Public Relations Committee</b></p>	<p><b>B. Zagnit, Chair</b></p>	<p><b>Public Relations Committee Update:</b></p> <p>The Annual Continuing Education Breakfast will be held in October with 3 speakers confirmed. Space for 150 attendees has been contracted. This year there is a registration fee of \$10.00 required for attendance.</p> <p>The Maryland Association of Consultant Pharmacist conference was attended by D. Jones and J. Seeds. The Board received positive feedback from Pennsylvania pharmacists on the Maryland Board of Pharmacy attendance at a rented booth.</p>		
<p><b>D. Disciplinary</b></p>	<p><b>T. Robinson, Chair</b></p>	<p><b>Disciplinary Committee Update</b></p> <p><i>None at this time.</i></p>		
<p><b>E. Emergency Preparedness Task Force</b></p>	<p><b>S. Roy, Chair</b></p>	<p><b>Emergency Preparedness Task Force Update</b></p> <p><i>None at this time.</i></p>		
<p><b>IV. Other Business &amp; FYI</b></p>	<p><b>M. Gavgani, Board President</b></p>	<p><i>The Office of Health Care Quality will be hosting a meeting regarding proposed regulations on assisted living facilities, where D. Jones will represent the Maryland Board of Pharmacy.</i></p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
<b>V. Adjournment</b>	<b>M. Gavgani, Board President</b>	<p><b>The Public Meeting was adjourned at 11:19 AM.</b></p> <p><b>At 11:52 AM M. Gavgani convened a Closed Public Session to conduct a medical review of technician applications.</b></p> <p><b>C. The Closed Public Session was adjourned at 1:30 PM. Immediately thereafter, M. Gavgani convened an Administrative Session for purposes of discussing confidential disciplinary cases. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Administrative Session.</b></p>	No official motion to close	The Board voted to close the public meeting.